Liposomal amphotericin b for empirical therapy in patients with persistent fever and neutropenia

New England Journal of Medicine

Volumn 340, Issue 10, 1999, Pages 764-771

  Walsh, Thomas J ^a   Finberg, Robert W ^j   Arndt, Carola ^b   Hiemenz, John ^c   Schwartz, Cindy ^j   Bodensteiner, David ^d   Pappas, Peter ^e   Seibel, Nita ^f   Greenberg, Richard N ^g   Dummer, Stephen ^j   Schuster, Mindy ^h   Holcenberg, John S ^j   Dismukes, William E ⁱ  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^e University of Alabama at Birmingham   (United States)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF KENTUCKY   (United States)

^h HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j University of Alabama ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; FEMALE; FEVER; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGOR; SURVIVAL;

EID: 0033545538     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199903113401004     Document Type: Article

References (30)

1. Vartivarian SE, Anaissie EJ, Bodey GP. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis 1993;17:Suppl 2:S487-S491.
2. Andriole VT. Infections with Aspergillus species. Clin Infect Dis 1993; 17:Suppl 2:S481-S486.
3. Pannuti C, Gingrich R, Pfaller MA, Kao C, Wenzel RP. Nosocomial pneumonia in patients having bone marrow transplant: attributable mortality and risk factors. Cancer 1992;69:2653-62.
4. Pizzo PA. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med 1993;328:1323-32.
5. Hughes WT, Armstrong D, Bodey GP, et al. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-73.
6. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11.
7. The EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-72.
8. Karp JE, Merz WG, Charache P. Response to empiric amphotericin B during antileukemic therapy-induced granulocytopenia. Rev Infect Dis 1991;13:592-9.
9. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
10. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22:Suppl 2:S133-S144.
11. Francis P, Lee JW, Hoffman A, et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar lavage D-mannitol and serum galactomannan as markers of infection. J Infect Dis 1994;169:356-68.
12. Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991;28:Suppl B:83-91.
13. Walsh TJ, Yeldandi V, McEvoy M, et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 1998; 42:2391-8.
14. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994; 86:754-60
15. Ng TTC, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch Intern Med 1995;155:1093-8.
16. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991;28:Suppl B:73-82.
17. Pizzo PA, Armstrong D, Bodey G, et al. The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel. J Infect Dis 1990;161: 397-401.
18. Walsh TJ, Hiemenz J, Pizzo PA. Evolving risk factors for invasive fungal infections - all neutropenic patients are not the same. Clin Infect Dis 1994;18:793-8.
19. Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996;100:617-23.
20. Nguyen MH, Clancy CJ, Yu VL, et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998;177: 425-30.
21. Arning M, Heer-Sonderhoff AH, Wehmeier A, Schneider W. Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia. Eur J Clin Microbiol Infect Dis 1995;14:41-3.
22. Levine SJ, Walsh TJ, Martinez A, Eichacker PQ, Lopez-Berestein G, Natanson C. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 1991;114:664-6.
23. Mehta R, Lopez-Berestein G, Hopfer R, Mills K, Juliano RL. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 1984;770:230-4.
24. Proffitt RT, Satorius A, Chiang SM, Sullivan L, Adler-Moore JP. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991;28:Suppl B:49-61. [Erratum, J Antimicrob Chemother 1992;29:355.]
25. Lee JW, Amantea MA, Francis P, et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 1994;38:713-8.
26. Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother 1994;38:223-7. [Erratum, Antimicrob Agents Chemother 1994;38:2230.]
27. Perkins WR, Minchey SR, Boni LT, et al. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta 1992;1107:271-82.
28. Adler-Moore JP, Proffitt RT. Development, characterization, efficacy, and mode of action of AmBisome, a unilamellar formulation of amphotericin B. J Liposome Res 1993;3:429-50.
29. Louie A, Baltch AL, Franke MA, Smith RP, Gordon MA. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone. J Antimicrob Chemother 1994;34:975-87.
30. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995;38:459-65.